FDA Panel Leans Toward More Trials For Ranexa, Doesn't Vote

GAITHERSBURG, Md. - An FDA panel generally agreed that Ranexa, CV Therapeutics Inc.'s candidate for chronic angina, is approvable if the company is willing to conduct another clinical trial in a broader population that includes patients who are not resistant to traditional drugs. (BioWorld Today)